Next-Gen Oral HDAC6i

About Avstera Therapeutics

Avstera Therapeutics is a private, clinical-stage biotech founded in 2018, focusing on oral small molecule therapies targeting RNA-binding proteins and HDAC6 for immuno-oncology and other diseases. Its lead asset, AVS100, is an IND-cleared, highly selective oral HDAC6 inhibitor for solid tumors, with a preclinical pipeline extending into cardiometabolic indications. The company is led by founder-CEO Karthik Musunuri and co-founder Ajay Raju, leveraging a foundation in immunology and strategic residency at J&J JLABS to advance its programs.

Therapeutic Areas